| Literature DB >> 25819469 |
Hyunggun Kim1, Patrick H Kee1, Yonghoon Rim1, Melanie R Moody1, Melvin E Klegerman1, Deborah Vela2, Shao-Ling Huang1, David D McPherson1, Susan T Laing3.
Abstract
The aim of this study was to determine whether pre-treatment with nitric oxide-loaded echogenic liposomes (NO-ELIP) plus ultrasound can improve highlighting by molecularly targeted (anti-vascular cell adhesion molecule 1 [VCAM-1]) ELIP of atheroma components. Atherosclerotic animals were treated with anti-VCAM-1-ELIP or immunoglobulin (IgG)-ELIP. Each group was selected at random to receive pre-treatment with standard ELIP plus ultrasound, NO-ELIP without ultrasound and NO-ELIP plus ultrasound. Intravascular ultrasound highlighting data for the same arterial segments were collected before and after treatment. Pre-treatment with NO-ELIP plus ultrasound resulted in a significant increase in acoustic enhancement by anti-VCAM-1-ELIP (21.3 ± 1.5% for gray-scale value, 53.9 ± 3.1% for radiofrequency data; p < 0.001 vs. IgG-ELIP, p < 0.05 vs. pre-treatment with standard ELIP plus ultrasound or NO-ELIP without ultrasound). NO-ELIP plus ultrasound can improve highlighting of atheroma by anti-VCAM-1 ELIP. This NO pre-treatment strategy may be useful in optimizing contrast agent delivery to the vascular wall for both diagnostic and therapeutic applications.Entities:
Keywords: Atheroma; Contrast agent; Contrast echocardiography; Early atherosclerosis; Molecular imaging; Nitric oxide; Ultrasound; Vascular cell adhesion molecule
Mesh:
Substances:
Year: 2015 PMID: 25819469 PMCID: PMC4426087 DOI: 10.1016/j.ultrasmedbio.2015.02.002
Source DB: PubMed Journal: Ultrasound Med Biol ISSN: 0301-5629 Impact factor: 2.998